Alzheimer’s Drug That Slows Cognitive Decline Gets FDA Approval

The Food and Drug Administration (FDA) last Friday approved an Alzheimer’s drug shown in clinical trials to slow cognitive decline in patients in the early stages of the illness. The approval offers patients renewed hope after repeated failures to find effective treatments, even though there have been reports of side effects with the new drug, experts say. The drug, lecanemab, which will be sold under the name Leqembi, is a monoclonal antibody infusion given every two weeks. The FDA approved Leqembi for use in people with mild cognitive impairment or early Alzheimer’s disease. Read more from NBC here.